Use of dual nucleic acid amplification tests (NAATs) for chlamydia and gonorrhoea
- Public Health England
- Part of:
- Gonorrhoea: guidance, data and analysis, Sexually transmitted infections (STIs): surveillance, data, screening and management, and Chlamydia: surveillance, data, screening and management
- First published:
- 13 August 2014
A report on the use of dual NAATs for chlamydia and gonorrhoea on samples collected for the National Chlamydia Screening Programme (NCSP).
PDF, 1.02MB, 31 pages
This file may not be suitable for users of assistive technology. Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email firstname.lastname@example.org. Please tell us what format you need. It will help us if you say what assistive technology you use.
This report presents results from a national survey of local authority commissioners which found that use of dual NAATs on samples collected for chlamydia screening by the NCSP is now widespread, despite there being no change in NCSP policy. The report highlights considerable variation across England in the clinical pathways for managing those testing positive for gonorrhoea.
In light of the findings of this report, PHE has published revised guidance for the detection of gonorrhoea in England, including guidance on the use of dual NAATs for chlamydia and gonorrhoea. The guidance aims to inform the commissioning and clinical delivery of gonorrhoea testing in England by recommending best practice.
Published: 13 August 2014